Stryker Corporation $SYK Shares Sold by Mar Vista Investment Partners LLC

Mar Vista Investment Partners LLC lowered its position in Stryker Corporation (NYSE:SYK) by 5.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 84,862 shares of the medical technology company’s stock after selling 5,325 shares during the quarter. Stryker accounts for approximately 2.6% of Mar Vista Investment Partners LLC’s holdings, making the stock its 18th biggest holding. Mar Vista Investment Partners LLC’s holdings in Stryker were worth $33,574,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Nuveen LLC acquired a new stake in shares of Stryker in the first quarter valued at approximately $558,075,000. Price T Rowe Associates Inc. MD lifted its stake in Stryker by 9.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after buying an additional 1,021,496 shares in the last quarter. Alliancebernstein L.P. lifted its stake in Stryker by 66.7% in the 1st quarter. Alliancebernstein L.P. now owns 1,373,142 shares of the medical technology company’s stock valued at $511,152,000 after buying an additional 549,643 shares in the last quarter. Vanguard Group Inc. grew its holdings in Stryker by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock valued at $12,306,572,000 after buying an additional 361,136 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in Stryker by 13.1% during the first quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock worth $838,640,000 after buying an additional 261,058 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 276,173 shares of the firm’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the transaction, the director directly owned 2,702,108 shares in the company, valued at $954,600,714.24. This trade represents a 9.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 520,500 shares of company stock valued at $184,803,065. 5.90% of the stock is owned by company insiders.

Stryker Price Performance

Stryker stock opened at $362.39 on Friday. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The firm has a 50 day moving average price of $371.96 and a 200 day moving average price of $381.22. The company has a market cap of $138.59 billion, a price-to-earnings ratio of 48.00, a PEG ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. During the same quarter last year, the firm posted $2.87 earnings per share. Stryker’s revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Sell-side analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on SYK shares. Redburn Partners set a $420.00 price objective on Stryker in a research report on Thursday, September 18th. Weiss Ratings restated a “hold (c+)” rating on shares of Stryker in a report on Thursday. Needham & Company LLC reiterated a “buy” rating and set a $448.00 price target on shares of Stryker in a report on Friday. Wells Fargo & Company upped their price objective on shares of Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a research note on Friday. Finally, Rothschild & Co Redburn began coverage on shares of Stryker in a research report on Thursday, September 18th. They set a “neutral” rating and a $420.00 target price on the stock. Thirteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $434.37.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.